Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protykin is a standardized natural extract derived from *Polygonum cuspidatum* (Japanese knotweed), developed by InterHealth Nutraceuticals (now part of Lonza). It is characterized by a high concentration of bioactive compounds, specifically standardized to contain 20% trans-resveratrol and 10% emodin. As a dietary supplement ingredient, it is primarily utilized for its antioxidant and phytoestrogenic properties. Research indicates its potential in providing cardioprotection through free radical scavenging activity during ischemic injury. Additionally, it is marketed for managing menopausal symptoms, such as hot flashes and mood swings, by helping to maintain normal estrogen activity and supporting healthy bone density. It is typically used as an ingredient in various formulations for cardiovascular health and menopausal support rather than as an approved pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Protykin.